India Caps Margins on 137 Cancer Drugs, Prices May Fall up to 70%

Cancer treatment in India is about to get cheaper for many patients. The drug pricing regulator has capped the margins that traders can add to 137 cancer medicines, and the government says prices of some of them could fall by as much as 70 percent.

The National Pharmaceutical Pricing Authority notified the cap over the weekend. From November 9, 2026, the trade margin on the 137 medicines will be limited to 30 percent of the maximum retail price, excluding GST. In plain terms, distributors, stockists and chemists together cannot add more than that slice between the factory gate and the patient's bill. The authority said the cap equals a maximum markup of 42.86 percent on the price at which a manufacturer sells to a stockist.

The medicines were picked by an expert committee of the Health Ministry as essential for cancer treatment. The list includes widely used drugs such as bevacizumab, pembrolizumab, nivolumab, osimertinib and palbociclib, plus denosumab and pegfilgrastim. The immunotherapy drugs on the list are used against more than 20 types of cancer, including breast, prostate, colon, ovarian and cervical cancers.

Most of these medicines were classed as non-scheduled drugs, outside the government's regular price controls. That freedom, the regulator said, had led to high mark-ups along the supply chain. To act, the authority used Paragraph 19 of the Drugs (Prices Control) Order, 2013, which lets the government step in on prices in the public interest. The list can be revised over time.

Manufacturers must tell the authority their revised prices within seven days of the Gazette notification, and retailers and hospitals must charge the new prices from November 9 and display them. Patients can check the revised prices on the Pharma Sahi Daam app and the authority's website.

The move builds on a 2019 decision that capped margins on 42 anti-cancer drugs and cut some prices by as much as 90 percent, according to Reuters.

Reaction

The drug industry's main lobby gave the decision a careful welcome. Sudarshan Jain, secretary general of the Indian Pharmaceutical Alliance, backed the balance between keeping medicines affordable for patients and leaving viable margins for the supply chain, while warning against any break in supply of cancer drugs.

Hospitals were cooler. Abhay Soi, chairman of Max Healthcare, warned that capping the margin on individual drugs, without counting the full cost of cancer care, from specialist staff to safe drug preparation and monitoring, could strain hospital finances.

For patients, the test is simple: whether the MRP printed on the pack actually drops from November 9, and by how much. The government promise is up to 70 percent on some medicines, not on all. The first revised price lists, due within days, will show the real number.